Wade MR: Difference between revisions
From Bioblast
Beno Marija (talk | contribs) |
|||
| (2 intermediate revisions by one other user not shown) | |||
| Line 12: | Line 12: | ||
|mailaddress=wade_mark_robert@lilly.com | |mailaddress=wade_mark_robert@lilly.com | ||
}} | }} | ||
{{Labelingperson}} | {{Labelingperson | ||
|field of research=Pharmacological | |||
}} | |||
== Participated at == | == Participated at == | ||
* [[MiPNet20.05 IOC104 Greenville |IOC104 Greenville]] | ::::* [[MiPNet20.05 IOC104 Greenville |IOC104 Greenville NC US]] | ||
::::* [[MiPNet19.06 IOC91 Philadelphia US |IOC91 Philadelphia US]] | |||
Latest revision as of 11:09, 14 February 2018
| Name | Wade Mark, |
|---|---|
| Institution | Eli Lilly and Co.
Lilly Corporate Center/DC0545 |
| Address | 893 S Deleware, 46285 |
| City | Indianapolis |
| State/Province | Indiana (IN) |
| Country | USA |
| wade_mark_robert@lilly.com | |
| Weblink | |
| O2k-Network Lab | US IN Indianapolis Brozinick JT |
Labels:
Field of research: Pharmacological
Publications
Add references to your publications
